Group 1 received 5 mg solifenacin per day	Group 2 received 4 mg fesoterodine per day	discontinuation of drugs due to side effects	1207	1320	The discontinuation rate of medication due to its side effects was 0 (0%) for Group 1, and 6 (10.2%) for Group 2.
Group 1 received 5 mg solifenacin per day	Group 2 received 4 mg fesoterodine per day	discontinuation of drugs due to side effects	9857	10013	The discontinuation of drugs due to side effects was of 0 in Group 1, and 6 in Group 2, and it was significantly more common in Group 2 (p=0.013) (Table 4).
Group 1 received 5 mg solifenacin per day	Group 2 received 4 mg fesoterodine per day	overactive bladder (OAB) symptom scores (OABSS)	821	1206	Average OABSS (score 1) was determined as: 9.5 ± 2.8 for Group 1 and 10.7 ± 1.8 for Group 2 at week 0; 2.2 ± 1.2 (Group 1) and 2.4 ± 1.3 (Group 2) at week 4 (score 2); and 1.3 ± 0.5 for Group 1 and 1.3 ± 0.6 for Group 2 at week 12 (score 3). In addition, no statistically significant difference was found between the scores (p=0.062 (score 1), p=0.464 (score 2), and p=0.527 (score 3).
Group 1 received 5 mg solifenacin per day	Group 2 received 4 mg fesoterodine per day	discontinuation of drugs due to side effects	1530	1618	However, discontinuation of drugs due to side effects was more frequent in fesoterodine.
